Abstract
Phosphatase Drugs The reversible phosphorylation of proteins controls all aspects of life. Targeting phosphorylation offers a broad range of therapeutic opportunities. Although kinases are among the most prevalent drug targets, phosphatases have traditionally been overlooked. Krzyzosiak et al. used surface plasmon resonance to develop a method to enable target-based discovery of serine/threonine phosphatases. The method identified Raphin1, a selective inhibitor of the regulatory subunit of protein phosphatase 1, PPP1R15B, a negative regulator of protein quality control. Raphin1 boosted protein quality control in cells and slowed down disease progression in a mouse model of Huntington's disease. Cell 174 , 1216 (2018).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
